International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia

International Journal of Clinical Practice

Volumn 53, Issue 4, 1999, Pages 243-250

  Betteridge, D J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033062122     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Shepherd J, Cobb SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
2. Pedersen TR and the Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
4. Bischoff H, Angerbauer R, Faggiotto A et al. Cerivastatin, a new highly potent and liver selective inhibitor of HMG-CoA reductase. Abstract presented at the 66th Congress of the European Atherosclerosis Society, Florence, Italy, July 13-17, 1996.
5. Duggan DE, Vickers S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev 1990; 22: 333-362.
6. Stein E, Sprecher D, Allenby KS et al. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg/daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Therapeut 1997; 2: 7-16.
7. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-373.
8. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-co-enzyme A reductase. Am J Cardiol 1994; 73: 3D-11D.
9. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol 1998; 81: 582-587.
10. Insull W, Stein E, Whalen E et al. Cerivastatin, a potent new HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolemia. Poster presented at the American College of Cardiology 46th Annual Scientific Session, Anaheim, California, March 16-19, 1997.
11. Stein E. Cerivastatin and primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol 1998; 82: 40J-46J.
12. Stein E, Isaacsohn J, Stoltz R et al. Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitor. 47th Scientific session of the American College of Cardiology 1998. Abstract 254470.
13. Vormfelde SV, Gleiter CH, Freudenthler S, Mück W et al. Pharmacokinetics of single dose cerivastatin in subjects with normal and impaired renal function. Atherosclerosis 1997; 130: S33.
14. Lettieri J, Krol G, Mazzu A et al. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis 1997; 130: S29.
15. Schall R, Müller O, Hondt HKL et al. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol 1995; 36: 306-313.
16. Frey R, Ritter W, Unger S et al. Phase I study to investigate the effects of cimetidine on the pharmacokinetics of cerivastatin: a new HMG-CoA reductase inhibitor. Atherosclerosis 1997; 130: S27.